|
|
|
Dear [Recipient’s name]
|
|
Were you able to watch our industry program about the latets innovations in pulmonary arterial hypertention (PAH)? If you missed it, you still ahve a chance to learn more about sotatercept, our investigational drug candidate. Sotatercept is a new investigational therapy in testing that may change the course fo PAH progression by rebalancing BMPR-II signaling. Find out how by viewing the full presentation–now available on the ATS YouTube page.
|
|
A New Direction in PAH:
|
|
A Potential Therapy for Rebalancing BMPR-II Signaling
|
|
|
|
Featuring Vallerie McLaughlin, MD, University of Michigan, Ann Arbor
|
|
Topic overview
|
|
Despite multiple treatment options, patients with PAH still face a devastating and progressive disease.
This program will focus on the imbalances in BMPR-II and activin receptor signaling that may drive PAH progression.
A new therapeutic approach that aims to rebalance this signaling will be discussed in the context of potential
disease modification.
|
|
|
Please be aware that this video is unlisted on the ATS YouTube page. You can only access the
video by clicking below.
|
|
|
|
|
|
|
Acceleron is passionate about accelerating the discovery of novel therapies that can help patients with PAH and other rare diseases. We hope you find this presentation helpful as we look to the future of PAH therapy.
|
|
If you have any questions about our clinical trials, eligibility, enrollment, or our pulmonary pipeline, feel free to contact us at 617-649-9200.
|
|
|
|